For health care professionals in EUROPE excepted those practicing in France as the following pages are intended to all International health care professionals and are not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Other health care professionals should select their country in the top right corner of the website.
Please note that the following pages are exclusively reserved for health care professionals in countries with applicable health authority product registrations. To the extent this site contains information, reference guides and databases intended for use by licensed medical professionals, such materials are not intended to offer professional medical advice. Prior to use, please consult device labeling for prescriptive information and operating instructions.
This Website is protected by the laws on copyright and by the relevant international conventions. It is strictly forbidden to make copies, whether partial or total and on whichever media without prior approval.
The video shows the diagnostic work-up with antegrade infusion, which finds a heavily diseased right SFA and short sub-total occlusion of an existing stent. After discussion, the strategy is to perform angioplasty with a RangerTM DCB and place a single 15 cm EluviaTM DES in the most diseased area of the artery which, also incorporates the existing short stent. After the procedure, the SFA is shown to be completely free of stenosis.
Advances in Drug-Eluting Technologies used for the treatment of coronary artery disease have been adapted for application in chronic peripheral lesions.
Having worked together on a case study Thomas Zeller, Koen Deloose and Jay Kokate discuss with Max Amor the PAD treatment options available today.
Download here: Eluvia™ peripheral stent system for the treatment of peripheral lesions above the knee. Prof. Stefan Müller-Hülsbeck.
Endovascular approaches for treating stenotic lesions of the peripheral arteries located above the knee (i.e. superficial femoral [SFA] and proximal popliteal arteries) invariably include the positioning of stents. However, the challenging biological environment means that restenosis or occlusion of the treated territory occur frequently requiring reintervention. The EluviaTM drug-eluting stent is designed to sustainably deliver an antiproliferative agent directly to the arterial tissue exactly when and where it is needed to reduce the incidence of restenosis.
Eluvia™ DES latest product brochure incorporating the new 2-year data from the MAJESTIC clinical trial available here.